期刊文献+

不同给药途径注射硝普钠对急性冠脉综合症患者经皮冠状动脉介入术中无复流的疗效 被引量:4

Curative effect of nitroprusside injection through different administration routes on no-reflow during percutaneous coronary intervention in patients with acute coronary syndrome
下载PDF
导出
摘要 目的:比较冠状动脉内经导引导管和经微导管注射硝普钠对急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)时无复流现象(NR)的疗效。方法选择四川省巴中市中心医院心内科2009年1月-2013年9月在实施PCI时出现靶血管NR的ACS患者55例,男性32例,女性23例。根据注射硝普钠的方式分为微导管组(n=31)和导引导管组(n=24),两组分别在NR时冠状动脉内注射硝普钠50μg/次,每2-5min重复直至NR消失。比较两组治疗前后TIMI血流分级、TIMI血流帧数(TFC)、不良反应和死亡的发生率。结果微导管组和导引导管组分别有29例(93.5%)和19例(79.2%)的患者TIMI血流分级改善,差异无统计学意义(P=0.22)。治疗后,微导管组TFC由(57.7±8.2)帧减少至(10.3±5.9)帧,导引导管组由(56.8±9.2)帧减少至(15.2±6.3)帧。两组治疗前后比较差异均有显著统计学意义(P均<0.01),且治疗后微导管组TFC明显低于导引导管组(P<0.05)。治疗后微导管组ITFC明显高于导引导管组[(0.82±0.11)vs.(0.73±0.11),P=0.004]。术后微导管组和导引导管组各有2例(6.5%)和5例(20.8%)住院期间死亡,差异无统计学意义(P>0.05)。微导管组和导引导管组各有3例(9.7%)和5例(20.8%)发生一过性低血压,两组低血压发生率差异无统计学意义(P>0.05)。结论经微导管注射硝普钠至靶血管远端治疗ACS患者PCI中NR疗效优于经导引导管。 Objective To compare the curative effect of intracoronary nitroprusside (NTP) injection through guiding catheter or micro-catheter on no-reflow (NR) during percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS).Methods The ACS patients with NR of target vessel during PCI were chosen (n=55, male 32 and female 23) from Jan. 2009 to Sept. 2013. All patients were divided into micro-catheter group (n=31) and guiding catheter group (n=24), and given intracoronary NTP injection (50 μg/time) during NR and given again every 2 min to 5 min until NR disappeared. The TIMI flow grading, TIMI flow frame count (TFC), adverse reaction incidence and mortality were compared in 2 groups before and after treatment.Results There were 29 cases (93.5%) in micro-catheter group and 19 (79.2%) in guiding catheter group with improved TIMI flow grading (P=0.22). After treatment, TFC decreased from (57.7±8.2) to (10.3±5.9) in micro-catheter group, and from (56.8±9.2) to (15.2±6.3) in guiding catheter group. The comparison between 2 groups before and after treatment had statistical difference (all P〈0.01), and TFC was significantly higher in micro-catheter group than that in guiding catheter group after treatment (P〈0.05). There were 2 cases (6.5%) in micro-catheter group and 5 (20.8%) in guiding catheter group died in hospital (P〉0.05). There were 3 cases (9.7%) in micro-catheter group and 5 (20.8%) in guiding catheter group with temporary hypotension (P〉0.05).Conclusion The curative effect of intracoronary NTP injection through micro-catheter is better than that through guiding catheter on NR during PCI in ACS patients.
出处 《中国循证心血管医学杂志》 2014年第6期747-750,共4页 Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词 硝普钠 无复流 急性冠状动脉综合征 经皮冠状动脉介入治疗 Nitroprusside No-reflow Acute coronary syndrome Percutaneous coronary intervention
  • 相关文献

参考文献15

  • 1Erkol A,Oduncu V,Turan B,et al. The value of plasma D-dimer level on admission in predicting no-reflow after primary percutaneous coronary intervention and long-term prognosis in patients with acute ST segment elevation myocardial infarction[J]. J Thromb Thrombolysis, 2014,38(3):339-47.
  • 2Dong M,Mu N,Guo F,et al. The beneficial effects of postconditioningon no-reflow phenomenon after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction[J]. J Throm blysis,2013,38(2):208-14.
  • 3Wong DT,Puri R,Richardson JD,et al. Myocardial 'no-reflow'-- diagnosis, pathophysiology and treatment[J]. Int J Cardiol,2013,167 (5): 1798-1806.
  • 4Schwartz BG,Kloner RA. Coronary no reflow[J]. J Mol Cardiol,2012, 52(4):873-82.
  • 5Sainas P,Jimenez-Valero S,Moreno R,et al. Update in pharmacological management of coronary no-reflow phenomenon[J]. Cardiovasc Hematol Agents Med Chem,2012,10(3):256-64.
  • 6Muller O,Trana C,Eeckhout E. Myocardial no-reflow treatment[J]. Curr Vasc Phannacol,2013, 11(2):278-85.
  • 7Kobatake R,Sato T,Fujiwara Y,et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction[J]. Heart Vessels,2011,26(4):379-84.
  • 8Pasceri V,Pristipino C,Pelliccia F,et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction[J]. Am J Cardiol,2005, 95(11):1358-61.
  • 9Wang HJ,Lo PH,Lin JJ,et al. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction[J]. Catheter Cardiovasc Interv,2004,63(2): 171-6.
  • 10Omar S,Webb AJ. Nitrite reduction and cardiovascular protection[J]. J Mol Cell Cardiol,2014, 73:57-69.

二级参考文献48

  • 1刘玲梅,张梅.冠状动脉无复流现象的研究进展[J].中国心血管杂志,2007,12(1):64-67. 被引量:3
  • 2袁军,黄从新,王风,林英忠,徐广马,周丽珍.主动脉内球囊反搏对急诊冠脉介入术后无复流的治疗作用观察[J].广西医学,2007,29(5):660-662. 被引量:16
  • 3丛洪良,杜纪兵,齐学艳,张梅,王伟,陈树涛,周长钰,李广平,黄体钢.急性心肌梗死患者经皮冠脉介入术后无/慢复流发生与炎症[J].中华高血压杂志,2007,15(6):485-488. 被引量:16
  • 4Kloner RA,Ganote CE,Jennings RB.The" no-reflow" phenomenon after temporary coronary occlusion in the dog.J Clin Invest,1974,54(6):1496-1508.
  • 5Galiuto L,Lombardo A,Maseri A,et al.Temporal evolution and functiona out coe of no-reflow:sustained and spontaneously reversible patterns following successful coronary recanalisation.Heart,2003,89(7):731-737.
  • 6Borne JG,Applecart,Ice CC,et al.Controlee rediffusion of therenationally ischemic myocardium with leukocyte-depleted blood reduces stunning,the no-reflow phenomenon and infarct size.Thoracal Cardiographs Surg,1992,103:66-71.
  • 7Niccoli G,Andreotti F,Marzo F,et al.Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction.Eur J Clin Invest,2011,41 (11):1210-1219.
  • 8De Luca G,Suryapranata H,Stone GW,et al.Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction:a meta-analysis of randomized trials.Am Heart J,2007,153 (3):343-353.
  • 9Ali A,Cox D,Dib N,et al.Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction:30-day results from a multicenter randomized study.J Am Coll Cardiol,2006,48 (2):244-252.
  • 10De Rosa S,Cirillo P,De Luca G,et al.Rheolytic thrombectomy during percutaneous coronary intervention improves long-term outcome in high-risk patients with acute myocardial infarction.J Interv Cardiol,2007,20 (4):292-298.

共引文献18

同被引文献37

  • 1STEEN D L, OI)ONOGHUE M L. Lp-PLA2 inhibitors for the reduc- tion of cardiovascular events [ J ]. Cardiology and Therapy, 2013,2 (2) :125-134.
  • 2Ait-Oufella H, Mallat Z, Tedgui A. Lp-PLA2 and sPLA2: cardiovas- cular biomarkers[ J]. Med Sci (Paris) ,2014,30(5 ) :526-531.
  • 3BOHENSKY M, TACEY M, BRAND C, et al. Statin initiation and treatment non-adherence following a first acute' myocardial infarction in patients with inflammatory rheumatic disease versus the general population[ J]. Arthritis Res Ther,2014,16(5) :443.
  • 4GURUMURTHY P, BORRA S K,YERUVA R K, et al. Estimation of ischemia modified albumin (IMA) levels in patients with acute coro-nary syndrome [ J ]. Indian J Clin Bioch era, 2014,29 ( 3 ) : 367 -371.
  • 5GIBSON C M, PRIDE Y B, HOCHBERG C P, et al. Effect of inten- sive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention far acute coronary .syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I[ J]. J Am Coil Car- diol, 2009,54 ( 24 ) : 2290'-2295.
  • 6IKONOMIDIS I, KADOGLOU N N, TRITAKIS V, et al. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease [ J ]. Atheroscleresis ,2014,234 ( I ) : 34 -4 I.
  • 7JUNG S, KIM M, CHAE J S, et al. Carriage of the V279F homozygous genotype, a rare allele, within the gene encoding Lp-PLA2 leads to changes in circulating intermediate metabolites in individuals without metabolic syndrome [ J 1. J Atheroscler Thromb ,2014,21 ( 12 ) : 1243-1252.
  • 8JUNG S, KIM 0 Y, KIM M, et al. Age-related increase in alanine aminotransferase correlates with elevated levels of plasma amino acids, decanoylcarnitine, Lp-PLA2 Activity, oxidative stress, and arterial stiffness [ J ] : J Proteome Res,2014,13 (7) : 3467-3475.
  • 9KIM M,JEUNG S R,JEONG T S ,et al. Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D[J]. J Lipid Res ,2014,55(8) :1762-1771.
  • 10KIM M, JUNG S, KIM S Y, et al. Prehypertension-associated eleva- tion in circulating lysophosphatidlycholines, Lp-PLA2 activity, and oxidative stress[J]. PLoS One ,2014,9 ( 5 ) :e96735.

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部